Miconazole%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is an imidazole antifungal agent. Its use in a vaginal pessary form is typically for the treatment of vaginal yeast infections (vulvovaginal candidiasis). ## Primary Indications * Treatment of vulvovaginal candidiasis. ## Adult Dosing The miconazole vaginal pessary is typically available in strengths of 100 mg, 200 mg, and 1200 mg. * **100 mg pessary:** Insert one pessary vaginally at bedtime for 7 days. * **200 mg pessary:** Insert one pessary vaginally at bedtime for 3 days. * **1200 mg pessary:** Insert one pessary vaginally at bedtime as a single dose. Specific duration and strength may vary based on product formulation and clinical guidelines. ## Pediatric Dosing There is no established specific dosing for pediatric patients. Use in pediatric patients should be based on clinical judgment and relevant guidelines, with caution. ## Dose Adjustments No dose adjustments are typically needed for renal or hepatic impairment due to minimal systemic absorption. ## Contraindications * Hypersensitivity to miconazole or any component of the formulation. ## Adverse Effects * **Common:** Vaginal burning, itching, irritation, lower abdominal cramps. * **Less Common:** Headache, rash. ## Key Drug Interactions * **Warfarin:** Miconazole (especially oral but potentially topical) can inhibit CYP2C9, increasing warfarin levels and risk of bleeding. Monitor INR closely if coadministered. * **CYP3A4 Substrates:** Miconazole can inhibit CYP3A4. Although systemic absorption is low with vaginal administration, potential for interaction exists, especially with prolonged or widespread use. ## Monitoring * Monitor for symptom resolution (itching, burning, discharge). * Monitor for adverse effects. * Monitor INR if used concurrently with warfarin. ## Clinical Pearls * Vaginal pessaries are inserted directly into the vagina. * Treatment duration depends on the strength of the pessary used. * Avoid sexual intercourse during treatment. * Consider recommending cotton underwear and avoiding douches or harsh soaps to prevent recurrence. * If symptoms persist after treatment, further evaluation for other causes or resistant organisms may be necessary. *** *Disclaimer: This information is intended for healthcare professionals. It is essential to consult the official prescribing information and relevant clinical guidelines for complete and up-to-date details before making any treatment decisions.*